GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Cyclically Adjusted Price-to-FCF

Cellectis (Cellectis) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cellectis's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Cyclically Adjusted Price-to-FCF Chart

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectis's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted Price-to-FCF falls into.



Cellectis Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cellectis's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Cellectis's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.313/118.2600*118.2600
=-0.313

Current CPI (Sep. 2023) = 118.2600.

Cellectis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 99.100 0.000
201306 0.000 99.700 0.000
201312 0.000 99.800 0.000
201406 0.000 100.180 0.000
201412 0.000 99.860 0.000
201503 -0.136 100.170 -0.161
201506 -0.532 100.440 -0.626
201509 -0.154 99.950 -0.182
201512 0.788 100.040 0.932
201603 -0.844 100.020 -0.998
201606 -0.363 100.630 -0.427
201609 -0.123 100.340 -0.145
201612 0.015 100.650 0.018
201703 -0.470 101.170 -0.549
201706 -0.334 101.320 -0.390
201709 -0.453 101.330 -0.529
201712 -0.279 101.850 -0.324
201803 -0.572 102.750 -0.658
201806 -0.310 103.370 -0.355
201809 -0.383 103.560 -0.437
201812 -0.544 103.470 -0.622
201903 -0.570 103.890 -0.649
201906 -0.571 104.580 -0.646
201909 -0.662 104.500 -0.749
201912 -0.130 104.980 -0.146
202003 -0.153 104.590 -0.173
202006 -0.852 104.790 -0.962
202009 -0.752 104.550 -0.851
202012 -1.175 104.960 -1.324
202103 -1.146 105.750 -1.282
202106 -0.387 106.340 -0.430
202109 -0.789 106.810 -0.874
202112 -0.451 107.850 -0.495
202203 -0.819 110.490 -0.877
202206 -0.543 112.550 -0.571
202209 -0.586 112.740 -0.615
202212 -0.032 114.160 -0.033
202303 -0.555 116.790 -0.562
202306 -0.345 117.650 -0.347
202309 -0.313 118.260 -0.313

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectis  (NAS:CLLS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cellectis Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cellectis's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Industry
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Launch of Follow-On Offering

By Stock market mentor Stock market mentor 02-02-2023

Cellectis Announces Pricing of Follow-On Offering

By Stock market mentor Stock market mentor 02-03-2023

Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

By Stock market mentor Stock market mentor 01-17-2023